Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01432015 · ClinicalTrials.gov registry record · Phase 4
Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting
A Phase 4 study, sponsored by Gynecologic Oncology Associates.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01432015 is a Phase 4 study that has completed, run by Gynecologic Oncology Associates. The registered enrollment target is 20 participants.
The verdict
NCT01432015, a Phase 4 study, has completed, sponsored by Gynecologic Oncology Associates.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with carboplatin and paclitaxel. The successful control of chemotherapy induced nausea and vomiting (CINV) is thus, of paramount importance in ensuring optimal treatment and sustaining a cancer patient's quality of life.
Interventions
- OTHER Oral Placebo
- DRUG aprepitant
- DRUG fosaprepitant
- OTHER IV placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-09 |
| Est. Completion | 2015-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01432015
The ClinicalTrials.gov registry entry for NCT01432015 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Associates, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Oral Placebo is the first listed.
NCT01432015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01432015 about?
NCT01432015 is a clinical study titled "Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting". Nausea and vomiting are two of the more concerning adverse outcomes associated with chemotherapy in the treatment of gynecologic malignancies. In fact, nearly 90% of cancer patients develop chemotherapy induced nausea and vomiting (CINV) following treatment with carboplatin and paclitaxel. The succe...
What is the current status of trial NCT01432015?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-09. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01432015?
The interventions under investigation include: Oral Placebo (OTHER), aprepitant (DRUG), fosaprepitant (DRUG), IV placebo (OTHER).
Who is sponsoring clinical trial NCT01432015?
This trial is sponsored by Gynecologic Oncology Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.